Evolus, Inc. (EOLS)

NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-10-23

$7.01-5.40%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Evolus, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	99.31M
EPS	—	0.066
FY 2026 · Annual
Revenue	—	334.15M
EPS	—	-0.048
Operating expenses	$210M–$216Mnon-GAAP	—
FY 2027 · Annual
Revenue	—	392.2M
EPS	—	0.328

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve low- to mid-single digit Adjusted EBITDA margin in 2026	It plans a low- to mid-single digit profit margin.	Improving	Adjusted EBITDA margin falls below low single digits in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Non-GAAP operating expenses are guided to $212M-$216M for 2026, a modest 1%-3% increase over 2025, while Adjusted EBITDA margin is expected to be low- to mid-single digit. Management is maintaining disciplined expense control consistent with this priority. Delivery assessment Oct 24, 2026
Move from negative to positive EPS by 2027	A supporting condition in Evolus, Inc.'s published investment case. The stated target is EPS >= $0.24.	Improving	EPS remains negative in FY27	Diluted EPS: $-0.12 per share FY2026-Q2; GAAP. Published target: EPS >= $0.24. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026-0.12 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: eba9b641-fbf5-4edf-adde-7f988f411361. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve revenue between $327M and $337M in 2026	A primary condition in Evolus, Inc.'s published investment case. The stated target is revenue between $327M and $337M.	Intact	revenue falls below $327M in FY26	Revenue: $84.084M FY2026-Q2; GAAP. Published target: revenue between $327M and $337M. Target period is not explicitly aligned with this observation. Source published Aug 5, 202684,084,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: eba9b641-fbf5-4edf-adde-7f988f411361. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Revenue grew from $68.5M in 2025-Q4 to $84.1M in 2026-Q2 quarterly, with full-year 2026 guidance raised to $330M-$337M, representing 11% to 13% growth over 2025. Management is delivering consistent revenue growth aligned with guidance. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

Unavailable → Unavailable · observed estimates

FY2027 revenueUnavailable

$0.39B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$387,666,143	4 / 5
2026-07-25	$0.24	$387,672,140	5 / 7
2026-07-26	Unavailable	$387,666,143	4 / 5
2026-07-27	$0.24	$387,672,140	5 / 7
2026-07-28	Unavailable	$387,666,143	4 / 5
2026-07-29	$0.24	$387,672,140	5 / 7
2026-07-30	Unavailable	$387,666,143	4 / 5
2026-07-31	Unavailable	$387,666,143	4 / 5
2026-08-01	Unavailable	$387,666,143	4 / 5
2026-08-02	$0.24	$387,672,140	5 / 7
2026-08-03	$0.24	$387,672,140	5 / 7
2026-08-04	$0.24	$387,672,140	5 / 7
2026-08-05	Unavailable	$387,666,143	4 / 5
2026-08-06	$0.24	$387,672,140	5 / 7
2026-08-07	Unavailable	$391,148,857	4 / 5
2026-08-08	Unavailable	$389,191,710	3 / 7
2026-08-09	Unavailable	$389,191,710	3 / 7
2026-08-10	Unavailable	$391,148,857	4 / 5
2026-08-11	Unavailable	$391,163,140	4 / 7
2026-08-12	$0.26	$391,148,860	5 / 7
2026-08-13	Unavailable	$391,148,857	4 / 5
2026-08-14	Unavailable	$391,148,857	4 / 5
2026-08-15	Unavailable	$391,148,857	4 / 5
2026-08-16	Unavailable	$391,148,857	4 / 5
2026-08-17	Unavailable	$391,148,857	4 / 5
2026-08-18	Unavailable	$391,148,857	4 / 5
2026-08-19	Unavailable	$391,148,857	4 / 5
2026-08-20	Unavailable	$390,679,833	4 / 5
2026-08-21	Unavailable	$390,679,833	4 / 5
2026-08-22	Unavailable	$390,679,833	4 / 5
2026-08-23	Unavailable	$390,679,833	4 / 5
2026-08-24	Unavailable	$390,679,833	4 / 5
2026-08-25	Unavailable	$390,679,833	4 / 5
2026-08-26	Unavailable	$391,429,143	4 / 5
2026-08-27	Unavailable	$391,429,143	4 / 5
2026-08-28	Unavailable	$391,429,143	4 / 5
2026-08-29	Unavailable	$391,429,143	4 / 5
2026-08-30	Unavailable	$391,429,143	4 / 5
2026-08-31	Unavailable	$391,429,143	4 / 5
2026-09-01	Unavailable	$391,429,143	4 / 5
2026-09-02	Unavailable	$391,429,143	4 / 5
2026-09-03	Unavailable	$391,429,143	4 / 5
2026-09-04	Unavailable	$391,429,143	4 / 5
2026-09-05	Unavailable	$391,429,143	4 / 5
2026-09-06	Unavailable	$391,429,143	4 / 5
2026-09-07	Unavailable	$391,429,143	4 / 5
2026-09-08	Unavailable	$391,429,143	4 / 5
2026-09-09	Unavailable	$391,429,143	4 / 5
2026-09-10	Unavailable	$391,429,143	4 / 5
2026-09-11	Unavailable	$391,429,143	4 / 5
2026-09-12	Unavailable	$391,429,143	4 / 5
2026-09-13	Unavailable	$391,429,143	4 / 5
2026-09-14	Unavailable	$391,429,143	4 / 5
2026-09-15	Unavailable	$391,429,143	4 / 5
2026-09-16	Unavailable	$391,429,143	4 / 5
2026-09-17	Unavailable	$392,200,667	4 / 5
2026-09-18	Unavailable	$392,200,667	4 / 5
2026-09-19	Unavailable	$392,200,667	4 / 5
2026-09-20	Unavailable	Unavailable	3 / 4
2026-09-21	Unavailable	Unavailable	3 / 4
2026-09-22	Unavailable	Unavailable	3 / 4
2026-09-23	Unavailable	Unavailable	3 / 4
2026-09-24	Unavailable	Unavailable	3 / 4
2026-09-25	Unavailable	Unavailable	3 / 4
2026-09-26	Unavailable	Unavailable	3 / 4
2026-09-27	Unavailable	Unavailable	3 / 4
2026-09-28	Unavailable	Unavailable	3 / 4
2026-09-29	Unavailable	Unavailable	3 / 4
2026-09-30	Unavailable	Unavailable	3 / 4
2026-10-01	Unavailable	Unavailable	3 / 4
2026-10-02	Unavailable	Unavailable	3 / 4
2026-10-03	Unavailable	Unavailable	3 / 4
2026-10-04	Unavailable	Unavailable	3 / 4
2026-10-05	Unavailable	Unavailable	3 / 4
2026-10-06	Unavailable	Unavailable	3 / 4
2026-10-07	Unavailable	Unavailable	3 / 4
2026-10-08	Unavailable	Unavailable	3 / 4
2026-10-09	Unavailable	Unavailable	3 / 4
2026-10-10	Unavailable	Unavailable	3 / 4
2026-10-11	Unavailable	Unavailable	3 / 4
2026-10-12	Unavailable	Unavailable	3 / 4
2026-10-13	Unavailable	Unavailable	3 / 4
2026-10-14	Unavailable	Unavailable	3 / 4
2026-10-15	Unavailable	Unavailable	3 / 4
2026-10-16	Unavailable	Unavailable	3 / 4
2026-10-17	Unavailable	Unavailable	3 / 4
2026-10-18	Unavailable	Unavailable	3 / 4
2026-10-19	Unavailable	Unavailable	3 / 4
2026-10-20	Unavailable	Unavailable	3 / 4
2026-10-21	Unavailable	Unavailable	3 / 4
2026-10-22	Unavailable	Unavailable	3 / 4
2026-10-23	Unavailable	Unavailable	3 / 4
2026-10-24	Unavailable	Unavailable	3 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	6	1
2026-06-01	6	1
2026-07-01	6	1
2026-08-01	6	1
2026-09-01	6	1
2026-10-01	5	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve low- to mid-single digit Adjusted EBITDA margin in 2026Direct metric needs a verified mapping
Move from negative to positive EPS by 2027Diluted EPS: $-0.12 per share
Achieve revenue between $327M and $337M in 2026Revenue: $84.084M

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.2%Typical daily move · historical

Downside history

-46.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Evolus, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth-oriented, loss-making business with elevated risk, rather than an established compounder. The long-term thesis is intact, though the recent signal has shifted from mildly favorable to mixed.

What's priced into Evolus, Inc.

The evidence describes EOLS as cheap versus peers, with no signs that the setup is fragile. Confidence in that valuation read is low, and the expectations gap suggests the market may already reflect more than the business is currently delivering.

What the fundamentals likely do

Near term, management is on track to reaffirm 2026 revenue guidance and reach a low- to mid-single-digit adjusted EBITDA margin, a measure of operating profit adjusted for certain items. Revenue has grown in recent quarters, while recent results were in line and the overall financial signal is now mixed. Risks include a reversal of the recent guidance increase and weaker employment data, which could raise recession concerns.

What Evolus, Inc. hinges on

Over the next 1 to 3 years, the thesis depends on continued revenue growth, expense control, and progress commercializing Profhilo, whose status is mixed. A guidance cut after the recent increase would challenge management credibility, while continued strength among healthcare peers could support the sector backdrop.